Biodesix, Inc. (BDSX) News
Track canonical SquawkNews coverage tagged to BDSX, Biodesix, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Biodesix, Inc. (BDSX) Advances Tumor-Informed and Tumor-Naïve MRD Programs
Biodesix announced progress on tumor-informed and tumor-naïve MRD solutions with Bio-Rad and Thermo Fisher, to be validated with MSK and designed for deployment on partner lab platforms.Material DetailsContext by AI Anal
NEWS | Sep 24, 2026, 10:01 AM UTC
L
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertiseLOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. NASDAQ:BDSX, a lead
NEWS | Sep 24, 2026, 10:01 AM UTC
L
BDSX - Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
BDSX - Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
NEWS | Sep 24, 2026, 10:00 AM UTC
L
BDSX - Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
BDSX - Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
NEWS | Sep 14, 2026, 08:01 PM UTC
L
Biodesix leadership to present at three upcoming investor conferences
Biodesix said members of its leadership team will present in three upcoming investor conferences, including Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG…).
EQUITY | Sep 03, 2026, 10:07 AM UTC
L
BDSX - Biodesix to Participate in Upcoming Investor Conferences
BDSX - Biodesix to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 10:00 AM UTC
L
Biodesix Affirms FY2026 Sales Guidance of $108.000M-$114.000M vs $110.996M Est
Biodesix (NASDAQ: BDSX ) affirms FY2026 sales outlook from $108.000 million-$114.000 million to $108.000 million-$114.000 million vs $110.996 million estimate.
EARNINGS | Aug 05, 2026, 08:02 PM UTC
L
BDSX - Biodesix Announces Second Quarter 2026 Results and Highlights
BDSX - Biodesix Announces Second Quarter 2026 Results and Highlights
EARNINGS | Aug 05, 2026, 08:01 PM UTC
M
BDSX: Roth Initiates Buy
Roth Capital initiates coverage on Biodesix with a Buy rating and a price target of $32
EQUITY | Jun 25, 2026, 11:00 AM UTC